|

COPD Clinical Trials in Charlotte, NC

15 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPDPhase 2<1 mi
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Phase 3<1 mi
A Study to Evaluate Solrikitug in Participants With COPD (ZION)Phase 2<1 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Phase 3<1 mi
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.Phase 4<1 mi
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDPhase 2<1 mi
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePhase 313 mi
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseasePhase 313 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)Phase 323 mi
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)Phase 223 mi
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)Phase 323 mi
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseasePhase 123 mi
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePhase 235 mi
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypePhase 339 mi
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypePhase 345 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.